Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24565981 | 0.89 | GPBAR1 (0.39) | GPBAR1PPARDMRGPRX4SCN9AULK1 | |
| SCHEMBL19705749 | 0.87 | GPBAR1 (0.38) | GPBAR1PPARDMRGPRX4ULK1NR1H4 | |
| SCHEMBL19705735 | 0.83 | GPBAR1 (0.42) | GPBAR1PPARDNAMPTMRGPRX4SCN9A | |
| SCHEMBL19698958 | 0.82 | GCG (0.43) | EPHX2KDM4E | |
| SCHEMBL19705941 | 0.81 | GPBAR1 (0.43) | GPBAR1PPARDNAMPTMRGPRX4ULK1 | |
| SCHEMBL19738283 | 0.80 | GPBAR1 (0.42) | GPBAR1PPARDNAMPTMRGPRX4ULK1 | |
| SCHEMBL19698929 | 0.79 | EGLN1 (0.43) | HPGDSKDM4EATM | |
| SCHEMBL19725195 | 0.79 | GPBAR1 (0.40) | GPBAR1PPARDNAMPTMRGPRX4ULK1 | |
| SCHEMBL25138292 | 0.77 | HDAC6 (0.50) | HDAC6 | |
| SCHEMBL15601900 | 0.73 | GPBAR1 (0.42) | GPBAR1MRGPRX4EPHX2HDAC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-06-30 | — | — | US | disclosed |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200369632-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10774054-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | GILEAD SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 493/4885 |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-11739065-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-20200369632-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | GPBAR1 6/4885PPARD 36/4885NAMPT 1234/4885 |
| US-20220204460-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
| US-10774054-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885NAMPT 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.